



Animals in Research Policy – Immunotherapy Challenge

At Ovarian Cancer Action we're on a mission to take action against the UK's most deadly gynaecological disease. Research involving animals has played a role in some of the biggest medical advances of our time. When there are no feasible alternatives, we fund research using animals as an essential part of our fight against ovarian cancer.

We are a member of the [Association of Medical Research Charities](#), which is committed to the refining, reducing and replacing the use of animals in research wherever possible. We fully support this commitment. We are committed to the principle of the 3Rs (Replacement Reduction, and Refinement).

We are based in the UK, and therefore we follow UK legislation in this area. Any research we fund which includes the use of animals must fully comply with the UK [Home Office guidelines](#).

Alternatives to animals must have been considered and detailed evidence of the potential benefits of the research must be provided to ensure that every test on an animal is absolutely necessary.

We will not fund research that does not comply with UK guidelines, for example research involving great apes, endangered species or very severe experimental procedures. Research using non-human primates must comply with the NC3Rs guidelines '[Non-human primate accommodation, care and use](#)'.

We expect grant holders to use the [ARRIVE guidelines](#) when designing their experiments and should ensure that they report animal-based studies in accordance with the ARRIVE guidelines as far as possible, taking into account the specific editorial policies of the journal concerned.

We will only fund research in countries outside the UK which have been deemed to have acceptable national standards of laboratory animal welfare. These are:

EU Member States

Switzerland

Norway

Australia

New Zealand

Canada

USA

Israel

Singapore

If you have any queries regarding this policy please contact the Research Team on immunotherapy@ovarian.org.uk or call +44 (0)20 7380 1730.